Welcome to our dedicated page for AEON Biopharma SEC filings (Ticker: AEON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AEON Biopharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AEON Biopharma's regulatory disclosures and financial reporting.
AEON Biopharma filed its Q3 2025 10‑Q, reporting continued operating losses and tight liquidity. The company posted a net loss of $4.5 million for the three months ended September 30, 2025, compared with a net loss of $6.2 million a year ago. Operating expenses declined as selling, general and administrative fell to $1.9 million and research and development to $0.6 million.
Cash and cash equivalents were $5.9 million at September 30, 2025, up from $13 thousand at December 31, 2024, aided by a January 2025 public offering that generated net proceeds of $18.3 million and modest ATM issuances. The company disclosed “substantial doubt” about its ability to continue as a going concern.
AEON executed a 1‑for‑72 reverse stock split on February 24, 2025 and had 11,643,786 shares outstanding at September 30, 2025. In the offering, Series A and Series B warrants were issued with the exercise price reset to $8.06; 3,438,095 Series B warrants were cashlessly exercised, issuing 10,314,285 shares. Convertible notes with Daewoong totaled $15.0 million principal (fair value $17.1 million as of September 30, 2025, interest 15.79%). AEON is pursuing a Botox biosimilar pathway and held a BPD Type 2a FDA meeting on November 19, 2025.
AEON Biopharma furnished an update on its business by announcing financial results for the third quarter ended September 30, 2025. The company issued a press release with details, which is included as Exhibit 99.1 to this report.
The information in this update (including Exhibit 99.1) is furnished, not filed, under the Exchange Act. AEON’s Class A common stock trades on the NYSE American under the symbol AEON.
AEON Biopharma announced a private placement and a binding note exchange term sheet. The company agreed to sell equity and warrants at a purchase price of $0.9116 per Share (or $0.9115 per pre‑funded warrant). The first closing is expected the week of November 17, 2025, with 1,964,905 Shares (or pre‑funded warrants) to be issued.
The second closing, subject to stockholder approval and consummation of the Daewoong exchange, is expected to include 4,616,924 Shares (or pre‑funded warrants) and 6,581,829 Warrants. The Warrants are cash‑exercise only at $1.09392 per share and are exercisable for five years from the second closing; pre‑funded and true‑up warrants have a $0.0001 exercise price. Warrants include full‑ratchet anti‑dilution with a floor of $0.30387, and exercises are limited by a 9.99% beneficial ownership cap (electable up to 19.99% with notice).
AEON and Daewoong signed a binding term sheet to exchange Daewoong’s existing notes for a $1.5 million note due 2030, an estimated 23,103,694 Exchange Shares (assumes a January 15, 2026 vote), and 8,000,000 Warrants at $1.09392. AEON also agreed to file a resale registration statement within 20 days of the earlier of the second closing or a specified termination.
AEON Biopharma, Inc. furnished an investor presentation as part of a corporate update. On September 8, 2025, the company made a “Corporate Presentation” available in the investor relations section of its website and attached it as Exhibit 99.1. Management may use this presentation in future meetings to discuss the company. The materials include a slide on forward-looking statements that outlines important cautionary information. The presentation and related information are furnished, not filed, so they are not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced.
AEON Biopharma reported a period of transition as it pivots ABP-450 development toward a biosimilar pathway after discontinuing Phase 2 migraine trials in May 2024. The company completed a 1-for-72 reverse stock split and raised net proceeds of approximately $18.3 million from a January 2025 public offering and has an ATM program with about $49.8 million remaining. As of June 30, 2025, AEON held $8.4 million in cash and total assets of $11.7 million, against total liabilities of $27.5 million, resulting in a stockholders' deficit of $15.9 million. The company recorded a $75.6 million non‑cash loss on warrant issuance and recognized fair value movements on convertible notes and contingent consideration that materially affected reported (loss) income. Management discloses substantial doubt about the company’s ability to continue as a going concern and states additional financing will be required to advance analytical studies, a planned FDA BPD Type 2a meeting and further development of ABP-450.
AEON Biopharma, Inc. furnished an update on its business by announcing financial results for the second quarter ended June 30, 2025. The company disclosed that these results were communicated through a press release dated August 12, 2025, which is included as Exhibit 99.1 to this Form 8-K.
The press release is treated as "furnished" rather than "filed" under the securities laws, which means it is not automatically subject to certain liability provisions and is not incorporated into other filings unless specifically referenced. No detailed financial figures are included in this report itself; those appear in the accompanying press release.